LSTA
Lisata Therapeutics Inc. · NASDAQ
- Market cap
- $13.1M
Lisata Therapeutics Inc. (LSTA) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 10 wire items for LSTA, including 7 SEC filings, 2 press releases and news items and 1 insider trade. The most recent was published Nov 13, 2026.
LSTA rankings
Financial highlights
Full financials- Revenue, TTM
- $100.0K
- Revenue growth
- -90.7%
- Net income, TTM
- -$17.16M
- Net margin
- -17159.0%
- Free cash flow, TTM
- -$21.66M
- Cash
- $282.72M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks38-20%
2026-05-242026-11-15
Mix2190d
- SEC Filings11(52%)
- Other6(29%)
- Insider3(14%)
- Leadership1(5%)
Activity · 52 weeks6738 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECSEC Form 10-Q filed by Lisata Therapeutics Inc.10-Q - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECSEC Form S-3 filed by Lisata Therapeutics Inc.S-3 - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECSEC Form S-8 filed by Lisata Therapeutics Inc.S-8 - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECAmendment: Lisata Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K/A - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECSEC Form DEFA14A filed by Lisata Therapeutics Inc.DEFA14A - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECLisata Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- PRMarea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces MAR001 Reduces Triglycerides Without Worsening Glycemic Control in Phase 2b TYDAL-TIMI 78 Trial; Results Presented as AHA 2026 Late-Breaker and Published in The New England Journal of MedicinePart A of TYDAL-TIMI 78 Trial met all objectives, with statistically significant placebo-adjusted triglyceride reductions of 39.1%–45.5% across all three doses at Week 12 and up to 57.2% in participants with baseline triglycerides ≥300 mg/dL Reductions from baseline of up to 72.2% in participants with triglycerides ≥500 mg/dL strongly support MAR001’s potential in severe hypertriglyceridemia (sHTG); Part B of TYDAL-TIMI 78 trial now enrolling sHTG participants Favorable and differentiated safety profile, with adverse event rates similar to placebo and no worsening of HbA1c SOUTH SAN FRANCISCO, Calif. and LIBERTY CORNER, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, Inc. ("
- PRMarea Therapeutics, a Subsidiary of Lisata Therapeutics, to Participate in Upcoming November Investor ConferencesSOUTH SAN FRANCISCO, Calif. and LIBERTY CORNER, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, Inc. ("Marea"), a subsidiary of Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata"), a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that management will participate in the following investor conferences: Guggenheim Healthcare Innovation ConferencePresentation: Tuesday, November 10 at 11:30 a.m. ESTBoston, MA LifeSci Growth and Innovation Summit1x1 Meetings: Monday, November 16London, U.K. Jefferies Global Healthcare Conference LondonPresentatio
- SECSEC Form DEF 14A filed by Lisata Therapeutics Inc.DEF 14A - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- INSIDERSEC Form 3 filed by Lisata Therapeutics Inc.3 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
- SECSEC Form 8-K filed by Lisata Therapeutics Inc.8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- PRLisata Therapeutics Appoints Jeff Farrow to Board of DirectorsLIBERTY CORNER, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company") today announced the appointment of Jeffrey Farrow to its Board of Directors, effective October 13, 2026. Mr. Farrow fills a newly created seat, expanding the Board from seven to eight members. He was appointed as a Class III director upon the recommendation of the Nominating and Corporate Governance Committee and will also serve on the Audit Committee. The Board has determined that Mr. Farrow is independent under Nasdaq listing rules. "Jeff has helped take multiple companies from the clinic to approval and commercial launch, and he has led several of them through su
- PRLisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid TumorsLIBERTY CORNER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company, today announced that the United States Patent and Trademark Office ("USPTO") has granted a new Method of Use patent for certepetide [U.S. Patent No. 12,751,991] for the treatment of pancreatic cancer and other solid tumors, expiring May 2041. The newly issued patent, titled "Methods for Treating Pancreatic Cancer and Other Solid Tumors," expands Lisata’s intellectual property protection for certepetide. The patent covers administering the Company’s proprietary cyclic peptide in combination with at least one anti-cancer agent
- SECSEC Form PRE 14A filed by Lisata Therapeutics Inc.PRE 14A - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- PRMarea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of AcromegalyTrial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks, compared to the daily subcutaneous injections required by the current standard of care By directly blocking growth hormone signaling at the receptor level, MAR002 has the potential to deliver meaningful biochemical control for a broad population of acromegaly patients SOUTH SAN FRANCISCO, Calif. and LIBERTY CORNER, N.J., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, LLC ("Marea"), a subsidiary of Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata"), a clinical-stage biotechnology company
- SECSEC Form D filed by Lisata Therapeutics Inc.D - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- INSIDERNew insider Love Ted W claimed ownership of 19,260 shares (SEC Form 3)3 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
- INSIDERNew insider Lehrer-Graiwer Joshua claimed ownership of 27,808 shares (SEC Form 3)3 - LISATA THERAPEUTICS, INC. (0000320017) (Issuer)
- PRMarea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026SOUTH SAN FRANCISCO and LIBERTY CORNER, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, Inc. ("Marea"), a subsidiary of Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata"), a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that data from the Phase 2b TYDAL study of MAR001, a potential first-in-class monoclonal antibody targeting angiopoietin-like protein 4 (ANGPTL4), will be presented in a late-breaking science session at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6-9, 2026, in Chicago, Illinois. Pres
- SECLisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- PRLisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private PlacementCombined company to focus on developing first-in-class next-generation medicines for cardioendocrine diseases Marea has multiple late-stage clinical product candidates: MAR001/005 for severe hypertriglyceridemia (sHTG) currently in Phase 2b and MAR002 for the treatment of acromegaly which is advancing to a Phase 2 study Concurrent financing of $225 million from leading life sciences investors and other institutional investors projected to fund operations into 2028 LIBERTY CORNER, N.J., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata"), a clinical-stage pharmaceutical company, today announced that it has acquired Marea Therapeutics, Inc. ("Marea"), a
- SECSEC Form 10-Q filed by Lisata Therapeutics Inc.10-Q - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- PRLisata Therapeutics Provides Update Following Termination of Merger AgreementLisata has filed suit against Kuva Labs Inc. and its subsidiary seeking, among other things, damages for the benefit of its stockholders Lisata’s Board of Directors and management continues to evaluate strategic alternatives to enhance stockholder value In order to reduce operating expenses and preserve cash to pursue strategic alternatives, Lisata has implemented a reduction in force of approximately 72% of its full-time employees LIBERTY CORNER, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today p
- SECLisata Therapeutics Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update, Other Events8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
- SECLisata Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Other Events8-K - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
LSTA FAQ
8 questionsWhat is the latest news on LSTA?
In the last 30 days Quantisnow tracked 10 wire items for LSTA: 7 SEC filings, 2 press releases and news items and 1 insider trade. The most recent was published on November 13, 2026.What is LSTA revenue?
Lisata Therapeutics Inc. (LSTA) reported $100.0K of revenue for the twelve months ended Sep 30, 2026. That is down 90.7% from the year before. Revenue for fiscal 2025 was $170.0K.Is LSTA profitable?
No. Lisata Therapeutics Inc. reported a net loss of $17.16M for the twelve months ended Sep 30, 2026.How much cash and debt does LSTA have?
Lisata Therapeutics Inc. reported $282.72M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does LSTA stock trade?
Lisata Therapeutics Inc. (LSTA) is listed on NASDAQ.What sector and industry is LSTA in?
Lisata Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to LSTA?
Notable peers in the same industry include PCSA (Processa Pharmaceuticals Inc.), CRDF (Cardiff Oncology Inc.), SLS (SELLAS Life Sciences Group Inc.), ATRA (Atara Biotherapeutics Inc.). Compare LSTA side-by-side with any of them on Quantisnow.How can I track LSTA on Quantisnow?
Quantisnow aggregates Lisata Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LSTA to receive live email and push alerts on every new disclosure.